All jobs come with risks. Mine? Working with a team of capital-C Creatives, if my Teams video freezes and leaves me in an awkward mid-sentence pose, they will capture a screenshot and “enhance” it. #revvity #photoshop #AlaspoorYorick #champagnetroubles

Stories of bridging the gap from discovery to cure at Revvity.

One drop of blood can change everything. Next-generation sequencing is transforming newborn screening, helping detect rare, treatable conditions earlier than ever. For healthier beginnings, #ChallengeAccepted.

ms.spr.ly/63326tTXFr

#NewbornScreening #Genomics #Revvity

Each organoid holds vital clues about disease. We help researchers decode those signals and bring insights closer to potential treatment.
For breakthroughs in 3D, challenge accepted. Learn how early screening can change lives.
#ChallengeAccpeted #Organoids #Revvity bit.ly/3IaERT2

マテリアルズ・インフォマティクスの最前線で導入するSignals Oneの可能性 Revvity Signals Softwareが提供する統合SaaSソリューション“Signals One™”の活用を探るウェビナーを開催します。材料研究者必見！

マテリアルズ・インフォマティクスの最前線で導入するSignals Oneの可能性 #東京都 #千代田区 #マテリアルズ・インフォマティクス #Revvity #Signals_One

Revvity Signals Softwareが提供する統合SaaSソリューション“Signals One™”の活用を探るウェビナーを開催します。材料研究者必見！

Find the ducks - Revvity Booth at #ASGCT2025

We hid 5 Mardi Gras ducks in our booth at ASGCT - can you find them all? #Revvity #ASGCT2025

化学研究を自動化する新たな一歩。Signals NotebookのChemDraw機能とウェビナー開催 Revvityが提供するSignals NotebookのChemDraw機能がリニューアル。使いやすさ向上のポイントやウェビナー情報を詳しく解説します。化学研究の未来を先取りしよう！

化学研究を自動化する新たな一歩。Signals NotebookのChemDraw機能とウェビナー開催 #千代田区 #Revvity #ChemDraw #Signals_Notebook

Revvityが提供するSignals NotebookのChemDraw機能がリニューアル。使いやすさ向上のポイントやウェビナー情報を詳しく解説します。化学研究の未来を先取りしよう！

Revvity beats quarterly estimates on steady demand for medical equipment (Reuters) -Revvity reported first-quarter results above Wall Street estimates and maintained its full-year profit forecast on Monday, helped by steady demand from biotech clients for medical equipment used for drug research. The medical equipment maker, which generates over half its sales outside the United States, said revenues will benefit due to a weaker dollar and slightly raised its full-year sales outlook. While maintaining its annual profit forecast of $4.90 to $5 per share on an adjusted basis, the company now anticipates 2025 revenue to be between $2.83 billion and $2.87 billion, compared to the previous projection of $2.80 billion to $2.85 billion. Revvity’s "clean beat" leaves "very little to quibble with" in this macroenvironment, said Bernstein analyst Eve Burstein. Investors have said the biotech sector’s funding crunch, which was expected to improve this year, could be prolonged due to policy uncertainty from the Trump administration. Shares of Revvity have fallen 15.5% so far this year. "Our first-quarter performance positions us well for the remainder of the year as we continue to adapt to an evolving macroeconomic backdrop," said CEO Prahlad Singh. Larger peers Thermo Fisher Scientific (NYSE:TMO) and Danaher (NYSE:DHR), who also posted strong quarterly results last week, had warned of a potential hit to results due to a looming threat of tariffs and other uncertainty. The Massachusetts-based Revvity earned a quarterly adjusted profit of $1.01 per share, above analysts’ estimates of 95 cents per share, according to data compiled by LSEG. It reported first-quarter revenue of $664.8 million, slightly above estimates of $661.2 million. The company’s life sciences unit, which provides reagents and instruments for drug discovery and development, brought in revenue of $340.4 million, compared with estimates of $332 million.

Click Subscribe #Revvity #MedicalEquipment #Biotech #Healthcare #Investment

Register Today for the Next ICHS Virtual Education - Tuberculosis in Endemic Areas: Challenges, Innovations, and Future Directions

#revvity
Revvity
The National Centre for Infections in Cancer

Click here to register: www.ichs.org/event-6069138

We asked some of our folks at Revvity to give us the inside scoop. The question? What's a big challenge scientists face in 2025, and how can we help? #science #lifescience #Revvity

Revvity Signalsが新しいラボオートメーション製品を発表する！ Revvity Signalsが新たに販売を開始した機器統合ソリューション"Signals DLX™"。研究者の負担を軽減し、革新的なデータ管理を実現します。

Revvity Signalsが新しいラボオートメーション製品を発表する！ #東京都 #千代田区 #Revvity #Signals_DLX #Scitara_Corporation

Revvity Signalsが新たに販売を開始した機器統合ソリューション"Signals DLX™"。研究者の負担を軽減し、革新的なデータ管理を実現します。